Comparative Pharmacology
Head-to-head clinical analysis: ARBLI versus CEFEPIME IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARBLI versus CEFEPIME IN PLASTIC CONTAINER.
ARBLI vs CEFEPIME IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ARBLI (arbaclofen placarbil) is a prodrug of baclofen, a GABA-B receptor agonist. It acts presynaptically to inhibit excitatory neurotransmitter release and postsynaptically to reduce neuronal excitability, leading to muscle relaxation.
Cefepime is a fourth-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), particularly PBP 3. It demonstrates broad-spectrum activity against gram-positive and gram-negative bacteria, including Pseudomonas aeruginosa.
10 mg orally once daily.
1-2 g intravenously every 8-12 hours for moderate to severe infections; up to 2 g every 8 hours for severe infections or febrile neutropenia.
None Documented
None Documented
Terminal elimination half-life of 26 hours (range 20-32 h), supporting once-daily dosing; prolonged in hepatic impairment.
2.0–2.3 hours in adults with normal renal function; prolonged to 13–26 hours in end-stage renal disease.
Primarily biliary (>70%) and fecal elimination; renal excretion accounts for <5% of unchanged drug.
Renal: approximately 85% of the dose excreted unchanged in urine; biliary/fecal: less than 1%.
Category C
Category A/B
Cephalosporin Antibiotic
Cephalosporin Antibiotic